8,606 reports of this reaction
4.1% of all SACUBITRIL AND VALSARTAN reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for SACUBITRIL AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 8,606 FDA adverse event reports linking SACUBITRIL AND VALSARTAN to FATIGUE. This represents approximately 4.1% of all 209,561 adverse event reports for this drug.
SACUBITRIL AND VALSARTAN has an overall safety score of 85 out of 100. Patients taking SACUBITRIL AND VALSARTAN who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among SACUBITRIL AND VALSARTAN users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for SACUBITRIL AND VALSARTAN:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 8,606 FDA reports for SACUBITRIL AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 4.1% of all adverse event reports for SACUBITRIL AND VALSARTAN, making it a notable side effect.
If you experience fatigue while taking SACUBITRIL AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.